Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
Notified -
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2025-05-02, 15:59
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-03-14, 15:06
AMD Brings World-Class Performance of 4th Gen AMD EPYC™
New energy-efficient EPYC Embedded 9004 Series combines embedded system-optimized features, enhanced security and scalability up to 96 cores —Siemens and...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-21, 13:07
Kinarus Therapeutics Phase 2 KINFAST Covid-19 Clinical
KINFAST is evaluating KIN001 for reduction in severity and duration of Covid-19 symptomsKINFAST is actively enrolling in Germany/Switzerland Basel,...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-21, 04:21
AMD to Present at Morgan Stanley’s Technology, Media and
SANTA CLARA, Calif., Feb. 20, 2023 (GLOBE NEWSWIRE) -- Today, AMD (NASDAQ: AMD) announced that Mark Papermaster, chief technology officer and executive...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-13, 19:03
ONL Therapeutics to Present at the XXVth Biennial Meeting
Oral presentation will review the scientific rationale for Fas receptor inhibition, a unique mechanism-of-action, in the treatment of patients with...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-02, 19:05
ONL Therapeutics to Present at 2023 BIO CEO & Investor
ANN ARBOR, Mich., Feb. 02, 2023 (GLOBE NEWSWIRE) -- ONL Therapeutics, Inc., a clinical-stage biopharmaceutical company developing novel therapies for...
